Develops ready-to-use engineered T-cell and natural killer cell therapies for patients with autoimmune diseases and cancer.
Sources
10-K for FY2025, filed Feb 26, 2026
We are a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of off-the-shelf cellular immunotherapies…View ↗
Utilizing our iPSC product platform, we are developing off-the-shelf, multiplexed-engineered T-cell and natural killer (NK) cell product…View ↗
How Do They Make Money?
Pharmaceutical collaborators pay upfront and for research and preclinical work under collaboration agreements; government grants also provide revenue. The company has not earned revenue from therapeutic product sales or royalties.
Sources
10-K for FY2025, filed Feb 26, 2026
To date, we have not generated any revenues from therapeutic product sales or royalties. Our revenues have been derived from collaboration…View ↗
On September 14, 2018, we entered into the Ono Agreement for the joint development and commercialization of two iPSC-derived CAR T-cell…View ↗
Pharmaceutical companies collaborate with Fate on research, development and commercialization of cell therapy candidates; the Ono agreement covers joint development of candidates.
Sources
10-K for FY2025, filed Feb 26, 2026
We have also entered into collaborations with pharmaceutical companies to research, develop and commercialize off-the-shelf…View ↗
On September 14, 2018, we entered into the Ono Agreement for the joint development and commercialization of two iPSC-derived CAR T-cell…View ↗
Autoimmune focus
The older report described its pipeline for cancer and autoimmune disorders; the latest states an initial focus on autoimmune diseases and cancer while still describing cancer programs.
Sources
10-K for FY2022, filed Feb 28, 2023
We are a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of programmed cellular immunotherapies to…View ↗
Utilizing this therapeutic approach, we are advancing a cell therapy pipeline comprised of off-the-shelf, multiplexed-engineered…View ↗
10-K for FY2025, filed Feb 26, 2026
Our mission is to bring off-the-shelf cellular immunotherapies with disease-transforming potential initially to patients with autoimmune…View ↗
Design and develop off-the-shelf, multiplexed-engineered CAR T-cell immunotherapies that incorporate multiple novel mechanisms of action…View ↗